1. Wang M#, Zhen H#, Jiang X, Lu Y, Wei Y, Jin J, Li Q*.Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors.immunuty inflammation and disease.2022.9(4).1584-1595.SCI |
2. Zhang L#, Jiang L#, Yu L#, Li Q#, Tian X, He J, Zeng L, Yang Y, Wang C, Wei Y, Jiang X, Li J, Ge X, Gu Q, Li J, Wu D, Sadler AJ, Yu D, Xu D, Gao Y, Yuan X*, He B*.Inhibition of UBA6 by inosine augments tumour immunogenicity and responses.Nature communications.2022.13(1).5413.SCI |
3. Wei Y#, Zhang J#, Fan X#, Zheng Z#, Jiang X#, Chen D#,Lu Y, Li Y, Wang M, Hu M, Du Q, Yang L, Li H, Xiao Y, Li Y, Jin J, Wang D, Yuan X*, Li Q*.Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression.Frontiers in Immunology.2022.13(/).935552.SCI |
4. Ying Z#, Qi D#, Chaoran W, Min H, Miao W, Qin L*.PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis.Clinical and translational medicine.2022.18(/).1-12.SCI |
5. Lu Y, Yuan X, Wang M, He Z, Li H, Wang J*, Li Q*..Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.Journal of Hematology & Oncology.2022.15(1).47.SCI |
6. Wang M, Wei Y, Li Y, Li H, Jin J, Lu Y, Li Q*.Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism.Immunity, Inflammation and disease.2022.10(8).e626.SCI |
7. Wang M, Du Q, Jin J, Wei Y, Lu Y, Li Q*.LAG3 and its emerging role in cancer immunotherapy .Clin Transl Med.2021.11(3).e365.SCI |
8. Lu Y, Jin J, Du Q, Hu M, Wei Y, Wang M, Li H, Li Q*.Multi-omics analysis of the anti-tumor synergistic mechanism and potential application of immune checkpoint blockade combined with lenvatinib.Frontiers in Cell and Developmental Biology.2021.9(/).730240.SCI |
9. Du Q, Che J, Jiang X, Li L, Luo X, Li Q*.PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.Clin Breast Cancer.2020.20(1).e99-e111.SCI |
10. Li Y, Wei Y, Tang W, Luo J, Wang M, Lin H, Guo H, Ma Y, Zhang J, Li Q*. Association between the degree of fibrosis in fibrotic focus and the unfavorable clinicopathological prognostic features of breast cancer.PeerJ.2020.e8067.1-10.SCI |
11. Li Y, Dong K, Fan X, Xie J, Wang M, Fu S, Li Q*.DNT cell-based immunotherapy: progress and applications.Journal of Cancer.2020.11(13).3717-3724.SCI |
12. Du Q, Guo X, Wang M, Li Y, Sun X, Li Q*.The application and prospect of CDK4/6 inhibitors in malignant solid tumors.J Hematol Oncol.2020.13(1).41.SCI |
13. Wei Y, Li Y, Du Q, Peng X, Jin J, Guo H, Li Y, Li Q*.Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis.J Immunol Res.2020.2020.1-11.SCI |
14. Jiang X, Li L, Li Y, Li Q*.Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor.Journal of Cancer.2019.10(7).1764-1771.SCI |
15. Wei Y, Du Q, Jiang X, Li L, Li T, Li M, Fan X, Li Y, Kariminia S, Li Q*. Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis .Crit Rev Oncol Hematol.2019.138.178-189.SCI |
16. Zhao P, Li L, Jiang X, Li Q*.Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.J Hematol Oncol.2019.12(1).54.SCI |
17. Yang L, Jiang X, Yan H, Li Y, Zhen H, Chang B, Kariminia S, Li Q*.Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.BMC Gastroenterol.2018.18(1).1-9.SCI |
18. Li Q, Li L, Jiang X, Du Q, Li Y, Li T, Gong H, Cao B*.Characteristics and prognostic values of traditional pathological parameters and advanced molecular subtypes in women in Beijing with operable breast cancer: a retrospective analysis.BMJ Open.2018.8(11).1-8.SCI |
19. Li L, Zhang J, Jiang X, Li Q*.Promising clinical application of ctDNA in evaluating immunotherapy efficacy.Am J Cancer Res.2018.8(10).1947-1956.SCI |
20. Li L, Chang B, Jiang X, Fan X, Li Y, Li T, Wu S, Zhang J, Kariminia S, Li Q*.Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.BMC Cancer.2018.18(1).1-10.SCI |
21. Li Q, Zhang R, Yan H, Zhao P, Wu L, Wang H, Li T, Cao B.Prognostic significance of HER3 in patients with malignant solid tumors .Oncotarget.2017.8(40).1-12.SCI |
22. Yang L, Li Y, Shen E, Cao F, Li L, Li X, Wang X, Kariminia S, Chang B, Li H, Li Q*.NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.Int J Oncol.2017.51(5).1553-1562.SCI |
23. Zhen H, Yang L, Li L, Yu J, Zhao L, Li Y, Li Q*.Correlation analysis between molecular subtypes and Nottingham Prognostic Index in breast cancer.Oncotarget.2017.8(43).74096-74105.SCI |
24. Li Z#, Li Q#, Wu J, Wang M, Yu J.Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do.Molecules.2016.21(10).1331.SCI |
25. Li Q, Zhang L, Li X, Yan H, Yang L, Li Y, Li T, Wang J, Cao B*.The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer: HER1-4 protein expression and prognosis in pancreatic cancer.BMC Cancer.2016.16(1).910.SCI |
26. Li Q, Yan H, Zhao P, Yang Y, Cao B.Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.Scientific Reports.2015.5.15746.SCI |
27. 李琴, 赵鹏飞, 庞慧, 曹邦伟..NCCN指南在肿瘤学临床教学过程中的应用及临床价值.中国高等医学教育.2015.9.67-69.核心期刊 |
28. Qin Li, Zhenyan Yuan, Han Yan, Zhaoyang Wen, Ruixue Zhang, Bangwei Cao.Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.Clinical Therapeutics.2014.36(7).1054-1063.SCI |
29. 李琴, 赵鹏飞, 袁振龑, 曹邦伟..肿瘤内科临床教学过程中医学生循证医学思维的培养.中国高等医学教育.2014.8.103-104.核心期刊 |
30. 李琴, 闫涵, 赵鹏飞, 张瑞雪, 原振龑, 曹邦伟..吉西他滨联合铂类与吉西他滨单药治疗晚期胰腺癌疗效的系统比较.临床与实验医学杂志.2014.13(16).1317-1321.核心期刊 |
31. 李琴, 沈恩允, 王明群, 赵鹏飞, 原振龑, 曹邦伟..新型HER3单克隆抗体逆转胃癌HER2过表达N87细胞Lapatinib耐药的研究.临床与实验医学杂志.2014.13(15).1225-1228.核心期刊 |
32. Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao.Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.PLoS One.2014.9(8).e104346.SCI |
33. Liu W, Zheng J, Li Q*.Application of imaging modalities for evaluating neuroblastoma.J Pediatr Endocrinol Metab.2013.26(11-12).1015-1120.SCI |
34. Qin Li, Zhenyan Yuan, Bangwei Cao.The function of human epidermal growth factor receptor-3 and its role in tumors (Review).Oncology Reports.2013.30(6).2563-2570.SCI |
35. 李琴, 车娟娟, 李卉惠, 闫涵, 曹邦伟..案例教学法在肿瘤内科临床轮转医师教学中的应用与分析.中国高等医学教育.2013.6.104-105.核心期刊 |
36. Li Q, Yang J..Role of imaging methods in metastatic melanoma.Onkologie.2012.35(9).522-526.SCI |
37. 李琴, 王婧, 李卉惠, 苏强, 马颖杰, 赵志海 曹邦伟..前列腺特异性抗原、病理分级与前列腺癌骨转移的关系探讨.临床荟萃.2011.26(3).228-230.核心期刊 |
38. 李琴, 苏强, 王婧, 李卉惠, 马颖杰, 赵志海, 钱林学, 曹邦伟, 贾继东, 王宝恩..无创评估肝硬化患者食管和(或)胃底静脉曲张因素的分析.首都医科大学学报.2011.32(3).426-430.核心期刊 |
39. 李琴, 甄洪超, 李卉惠, 朱圣韬, 王婧, 李坤, 徐昌青, 曹邦伟..TBX-21基因启动子区多态性与食管鳞癌易感、临床病理特征的相关性研究.临床肿瘤学杂志.2011.16(6).487-491.核心期刊 |
40. 李琴, 曹邦伟, 郝瑞瑞, 苏强, 李卉慧, 王婧, 马颖杰..氟代脱氧葡萄糖联合线路单光子发射计算机断层显像在肺癌诊断中的价值.山西医药杂志.2010.10(39).939-940.核心期刊 |